Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million NIH Small Business Innovation Research (SBIR) grant for preclinical studies treating acute disseminated encephalomyelitis (ADEM), a neurologic disease principally of children.   Trethera’s clinical stage and first-in-class drug, TRE-515, holds the only FDA Orphan Drug designation for ADEM.   

In this issue:
- A new partnership with UCLA Ventures
- Funding updates for TORL, Pelage Pharmaceuticals, UCLA Samueli, and ImmPACT Bio
- A trip to the UCLA Research Park
- Event wrap ups for MedTech, LABEST and UCLA Ventures dinner
and more

Pelage Pharmaceuticals, a Los Angeles-based hair loss biotech based on research out of UCLA, has reeled in a $16.75 million Series A and plans to start a mid-stage trial later this year.

See full article below;